Journal article
Current status of MitraClip for patients with mitral and tricuspid regurgitation
Trends in cardiovascular medicine, Vol.28(3), pp.200-209
04/2018
DOI: 10.1016/j.tcm.2017.08.008
PMID: 28863973
Abstract
Mitral valve regurgitation (MR) affects approximately 4 million people in the United States alone, increasing in prevalence with age. Approved by the Food and Drug Administration (FDA) in October 2013, percutaneous edge-to-edge transcatheter mitral valve repair (also known as the MitraClip system) has been used in over 40,000 patients globally. Additionally, there is keen interest and early exploration into the use of MitraClip for treatment of severe symptomatic tricuspid regurgitation, another undertreated disease with significant morbidity and mortality. In this manuscript, we aim to review the current indications, procedural details as well as emerging indications for this novel technology.
Details
- Title: Subtitle
- Current status of MitraClip for patients with mitral and tricuspid regurgitation
- Creators
- Sidakpal S Panaich - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MNMackram F Eleid - Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Electronic address: Eleid.mackram@mayo.edu
- Resource Type
- Journal article
- Publication Details
- Trends in cardiovascular medicine, Vol.28(3), pp.200-209
- DOI
- 10.1016/j.tcm.2017.08.008
- PMID
- 28863973
- ISSN
- 1050-1738
- eISSN
- 1873-2615
- Language
- English
- Date published
- 04/2018
- Academic Unit
- Cardiovascular Medicine; Internal Medicine
- Record Identifier
- 9984094365902771
Metrics
21 Record Views